Severe Immune Thrombocytopenia (ITP)

Definition

Severe Immune Thrombocytopenia (ITP) is an autoimmune disorder characterized by:

  • A platelet count typically < 30,000/µL (often used clinically for “severe” disease)
  • Clinically significant bleeding, such as:
    • Mucosal hemorrhages (e.g., nosebleeds, gum bleeding)
    • Petechiae (small red spots on the skin)

In ITP, the immune system produces antibodies that destroy platelets, increasing the risk of serious internal bleeding.


Clinical Features

Common Symptoms

Mucosal bleeding  

Petechiae 

 Purpura (easy bruising)

--------------------------------------------------------- 

 Additional Patient-Reported Symptoms

  • Fatigue
  • Memory and concentration difficulties

These non-bleeding symptoms can significantly impact quality of life, highlighting the need for holistic treatment approaches.


Risks and Complications

Patients with severe ITP are at risk of:

  • Spontaneous hematomas
  • Severe gastrointestinal bleeding
  • Intracranial hemorrhage (life-threatening brain bleeding)

Diagnosis of Thrombocytopenia

Definition of Thrombocytopenia

Thrombocytopenia is defined as:

  • Platelet count < 150,000/µL

Underlying Mechanisms

  • Reduced platelet production (thrombopoiesis)
  • Increased platelet destruction (e.g., autoimmune causes like ITP)

If all blood cell lines are reduced:

  • Decreased erythropoiesis (red cells)
  • Decreased leukopoiesis (white cells)
  • Decreased thrombopoiesis (platelets)

→ This suggests a broader bone marrow or hematopoietic disorder.


Classification of ITP by Duration

  • Acute ITP: < 3 months
  • Persistent ITP: 3–12 months
  • Chronic ITP: > 12 months

Refractory Severe ITP

  • Does not respond to standard treatments
  • May persist even after splenectomy

Treatment of Severe ITP

Due to bleeding risk, urgent treatment is required, typically including:

  • Corticosteroids
  • Intravenous immunoglobulin (IVIG)
  • Other immunosuppressive therapies

Treatment goals:

  • Prevent bleeding
  • Increase platelet count
  • Improve quality of life

Acquired vs. Inherited Thrombocytopenia

Acquired Thrombocytopenia

  • Develops due to external factors:
    • Autoimmune diseases (e.g., ITP)
    • Medications
    • Infections

Inherited Thrombocytopenia

  • Genetic condition present at birth
  • Often features large platelets (macrothrombocytopenia)
  • Can be misdiagnosed as ITP

Misdiagnosis may lead to unnecessary immunosuppressive treatment


Drug-Induced Thrombocytopenia

Certain medications can cause low platelet counts. These include:

  • Some antibiotics
  • Heparin
  • Antiepileptic drugs
  • Chemotherapy agents

Dietary Considerations in Thrombocytopenia

To reduce bleeding risk, patients may be advised to avoid or limit:

Foods/Substances That May Affect Platelets

  • Alcohol
  • Quinine (found in tonic water)
  • Garlic
  • Onions
  • Ginger
  • Turmeric

Other Dietary Factors

  • Processed foods
  • High-sugar items
  • Trans fats

Some foods rich in antioxidants (e.g., blueberries, red grapes) may influence platelet function, though evidence is limited.


Key Takeaways

  • Severe ITP involves very low platelet counts and active bleeding risk
  • It is an autoimmune condition requiring prompt treatment
  • Diagnosis requires distinguishing it from other causes of thrombocytopenia
  • Management should address both bleeding symptoms and quality of life

References:

Immune Thrombocytopenia https://www.ncbi.nlm.nih.gov/books/NBK562282/

When you have ITP, the immune system is out of balance in more ways than one
https://www.wayrilz.com/us/what-is-itp

Refractory severe idiopathic thrombocytopenia and treatment challenges
https://pmc.ncbi.nlm.nih.gov/articles/PMC10129162/

Thrombocytopenia https://www.youtube.com/watch?v=i_c8x7TiHN0

Immune thrombocytopenia (ITP)
https://www.rarediseaseadvisor.com/hcp-resource/immune-thrombocytopenia-diet-nutrition/

Definition der ITP (German)
https://pro.campus.sanofi/de/immunthrombozytopenie-itp/wissen/itp-definition

Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol. 2021;96(2):188-198.

 

© 2000-2030 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a fife year copy right. Library of Congress Card Number: LCN 00-192742 ISBN: 0-9703195-0-9  

Comments

Popular posts from this blog

Schnitzler Syndrome: A Rare Autoinflammatory Disorder

Acute Flaccid Myelitis (AFM): Understanding the “Polio-like” Illness Affecting the Spinal Cord

Dysferlin Protein: Key Roles, Genetic Locations